REDEMPLO approved and commercially accelerating; the bet is whether Phase 3 sHTG data earns a label expansion into a market dwarfing FCS

Bull

FDA accepts the sNDA and grants priority review via the acquired voucher, with approval in approximately six months following submission; the label captures the acute pancreatitis risk-reduction data (78% event reduction versus placebo across the full sHTG population, 100% in highest-risk patients), enabling a compelling clinical and payer narrative. Approval would unlock a patient population many times larger than FCS, validating the One-REDEMPLO unified pricing strategy and driving a step-change in revenue trajectory beyond the current commercial ramp.

Bear

The FDA could request additional data, issue a Complete Response Letter, or narrow the label in ways that limit commercial reach — for example, restricting the indication to patients with prior acute pancreatitis history rather than the broader sHTG population. A label that excludes the pancreatitis risk-reduction claim, or that imposes REMS requirements elevating access barriers, would undermine the differentiation story versus standard-of-care fibrates and niacin and blunt the commercial opportunity relative to expectations.